Amwill Health Care Limited has announced approval for strategic investments totaling ₹5.25 crores, marking a significant step in the company's financial growth strategy. The Investment Committee approved these investments during its meeting held on January 16, 2026, with funds to be sourced from the company's internal accruals.

Investment Allocation Details

The approved investment plan encompasses two distinct investment avenues designed to diversify the company's portfolio and support long-term objectives.

Vivriti Fixed Income Fund Investment

The larger portion of the investment, amounting to ₹3.00 crores, will be allocated to subscribe to units of the Vivriti Fixed Income Fund. This fund operates as a scheme of Vivriti Vihaan Trust and is registered with SEBI as a Category II Alternative Investment Fund. The company expects this initiative to contribute positively to its financial growth while supporting operational objectives. The investment is proposed to be executed in the ensuing months.

Government Securities Investment

The remaining ₹2.25 crores will be invested in Government Securities and related investment products. This allocation specifically targets supporting the company's long-term growth strategy and will be funded through internal accruals. The investment in G-Sec products provides a stable investment avenue for the healthcare company.

Regulatory Compliance and Transparency

The company has confirmed that these investments do not involve any related party transactions, ensuring compliance with regulatory requirements. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, demonstrating the company's commitment to transparency.

Strategic Impact

These strategic investments represent Amwill Health Care's approach to optimizing its financial resources while maintaining focus on growth objectives. By diversifying into alternative investment funds and government securities, the company aims to create a balanced investment portfolio that supports both immediate operational needs and long-term strategic goals.

Amwill Health Care , a prominent player in the healthcare sector, has released its unaudited financial results for the half year ended September 30, 2025. The company reported a significant decline in profit and a decrease in revenue, while also providing an update on the utilization of its Initial Public Offering (IPO) proceeds.

Financial Performance

The company's financial performance for H1 FY2026 shows a notable decline compared to the same period in the previous year:

Amwill Health Care experienced a substantial 40.55% decrease in profit, dropping from ₹651.66 lakhs to ₹387.40 lakhs. This decline was accompanied by an 8.43% reduction in revenue from operations, which fell to ₹2,120.50 lakhs from ₹2,315.60 lakhs in the previous corresponding period.

Total expenses rose by 19.59% to ₹1,733.90 lakhs, with a significant increase in employee benefit expenses, which grew by 21.61% to ₹424.37 lakhs. As a result of these factors, earnings per share decreased from ₹4.18 to ₹1.94, representing a 53.59% decline.

IPO Proceeds Utilization

Amwill Health Care provided an update on the utilization of its IPO proceeds:

The company has utilized ₹3,288.08 lakhs of its total IPO proceeds of ₹4,888.00 lakhs, representing 67.27% of the funds raised. The remaining ₹1,599.92 lakhs are currently unutilized and have been invested in term deposits (₹1,546.61 lakhs) and kept in current accounts (₹53.30 lakhs).

Management Statement

In its statement to the Bombay Stock Exchange, the company confirmed that there has been no deviation or variation in the utilization of IPO proceeds from the objects stated in the Prospectus dated February 10, 2025. The Audit Committee has reviewed and approved this statement.

Amwill Health Care remains committed to its growth strategy and efficient use of resources. However, the significant decline in profit and increase in expenses may require careful monitoring in the coming quarters.